LB Pharmaceuticals Inc

Contributing Author

Recent Articles by LB Pharmaceuticals Inc

8 hours	LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors LBRX GlobeNewswire
Mar-04	LB Pharmaceuticals to Participate in Upcoming March Investor Events LBRX GlobeNewswire
Feb-10	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX GlobeNewswire
Feb-05	LB Pharmaceuticals Announces $100.0 Million Private Placement LBRX +12.71% GlobeNewswire
Jan-26	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program LBRX -6.40% GlobeNewswire
Jan-21	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel LBRX GlobeNewswire
Jan-12	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX -8.20% GlobeNewswire
Jan-06	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture LBRX GlobeNewswire
Dec-10	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX -5.29% LBRX GlobeNewswire
Dec-09	LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices LBRX GlobeNewswire
Nov-24	LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference LBRX +5.28% GlobeNewswire
Nov-12	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) LBRX -5.63% GlobeNewswire
Nov-12	LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer LBRX -5.63% GlobeNewswire
Nov-06	LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference LBRX GlobeNewswire
Nov-06	LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates LBRX GlobeNewswire
Oct-14	LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs LBRX GlobeNewswire
Oct-06	LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms LBRX GlobeNewswire
Sep-25	LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani LBRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)